Krystal Biotech, Inc. - Common Stock - Nakit Akışı (NASDAQ:KRYS) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -26.08 M-47.94 M-100.57 M-88.8 M123.42 M200.87 M 250.28 M Yatırım faaliyetlerinden elde edilen nakit -11.18 M-226.77 M-114.08 M82.64 M-163.44 M-58.42 M -67.23 M Finansman faaliyetlerinden elde edilen nakit 118.02 M347.69 M35.35 M202.75 M27.01 M8.71 M 10.71 M Serbest nakit akışı -26.08 M-47.94 M-100.57 M-88.8 M123.42 M188.91 M 237.38 M

Haberler

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Krystal Biotech hissesi 315,68 dolarda rekor kırdı

This Profitable Biotech Stealthily Climbs Into A Buy Zone

Krystal Biotech: Vyjuvek Is Not The Primary Asset (NASDAQ:KRYS)

Rocket Lab Soars 34%, Leads 10 Hot Prospects To IBD Best Stock Screens

Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:KRYS) 2026-05-06

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results - Krystal Biotech (NASDAQ:KRYS

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

BofA, Krystal Biotech hissesi için hedef fiyatı düşürdü

Krystal Biotech 1Ç 2026 kazanç beklentilerini aştı

Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates